Diagnostic Approach for Lymphedema
The diagnosis of lymphedema should be based on a combination of clinical assessment of limb volume/circumference changes, with diagnostic criteria including volume increase ≥10% or circumference increase ≥2 cm compared to the unaffected limb, and can be confirmed with specialized imaging when necessary. 1
Clinical Assessment
History and Risk Factors
- Identify history of:
- Cancer treatment (especially breast cancer, with radiation to lymph nodes) 2, 1
- Lymph node removal (5+ nodes significantly increases risk) 1
- Radiation therapy (particularly to supraclavicular, axillary, and internal mammary regions) 1
- Recurrent infections in the affected area 1
- Trauma to the affected limb 3
- Obesity (significant risk factor) 1
Physical Examination
- Assess for characteristic signs:
Objective Measurements
Circumferential Measurements
- Circumferential measurement should be used to diagnose upper extremity lymphedema (Stage 1 or greater) 2
- Diagnostic criteria: circumference increase ≥2 cm compared to unaffected limb 1
- For hand lymphedema: figure-of-8 method for assessment 2
- For head and neck lymphedema: measurement at single point under jawline 2
Volume Measurements
- Water displacement: diagnostic with >200 mL difference or >10% interlimb difference 2
- Calculated volume differential ≥200 ml helps rule in lymphedema 2
- If preoperative measures available: 5% or greater volume change from baseline above and below the elbow is diagnostic 2
- Volume ratio of 1.04 may indicate upper extremity lymphedema 2
Advanced Diagnostic Tools
Bioimpedance Analysis
- Should be used to detect lymphatic transport impairments and diagnose subclinical/early stage lymphedema (Stage 0 and 1) 2
- L-Dex score >7.1 is diagnostic when no preoperative assessment is available 2
- L-Dex score >10 above preoperative baseline is diagnostic 2
- Note: In moderate to late stage lymphedema with fibrosis, BIA results may show decreased extracellular fluid despite increased tissue volume 2
Imaging Studies
- Lymphoscintigraphy: Gold standard to detect lymphatic system impairment 2, 6
- Ultrasound: Should be used as a diagnostic tool to identify tissue changes 2
- MRI: May be used as a diagnostic tool 2
- CT: May be used as a diagnostic tool 2
- Lymphography: May be used to detect lymphatic system impairment 2
Not Recommended as Diagnostic Tools
- Perometry (useful for assessment but not diagnosis) 2
- Tissue Dielectric Constant (for assessment only) 2
- Dual-energy X-Ray Absorptiometry (for assessment only) 2
- Tonometry (not recommended) 2
Patient-Reported Symptoms
- Self-reported swelling, heaviness, and numbness should be investigated to facilitate early diagnosis 2
- Validated questionnaires that assist in diagnosis:
Staging and Classification
Once diagnosed, lymphedema should be staged:
- Stage 0: Subclinical (no visible swelling but impaired lymphatic transport)
- Stage 1: Reversible edema (pitting, subsides with elevation)
- Stage 2: Spontaneously irreversible edema (fibrosis begins)
- Stage 3: Lymphostatic elephantiasis (severe fibrosis, skin changes) 3
When to Refer
- Patients with clinical symptoms or swelling suggestive of lymphedema should be referred to a therapist knowledgeable about lymphedema diagnosis and treatment (physical therapist, occupational therapist, or lymphedema specialist) 2
- Referral to specialized lymphedema therapist is essential for optimal management 1
Common Pitfalls
- Misdiagnosing lymphedema as generic swelling or edema from other causes 4
- Failing to obtain baseline measurements before cancer treatment, which complicates later diagnosis 2
- Overlooking early, subclinical lymphedema when intervention would be most effective 1
- Not distinguishing between primary (congenital) and secondary (acquired) lymphedema, which may affect treatment approach 6, 7
- Neglecting to assess for complications like cellulitis/erysipelas, which require immediate antibiotic treatment 1, 5
By following this diagnostic approach, clinicians can accurately identify lymphedema and initiate appropriate management to prevent progression and complications that impact morbidity, mortality, and quality of life.